Exas is looking more and more comfortable in the foothold it currently has, but only in the US market. Do not assume it is going to last a generation.
I can guarantee things are happening much too quickly in the stem cell community to make that claim. This will be the next huge area of $$$ concentration that will actually yield results in all areas of medical endeavor, and not just to keep researchers busy.
News 
Market Data 
Discover 
